An Investing Breakthrough Years in the Making

Today's market action… The Magnificent Six… Important data on tap… The opportunity in biotech… An investing breakthrough years in the making... Rank almost 5,000 stocks and beat the market… [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [Stansberry Digest] [TOMORROW: Our Biggest Breakthrough in 25 Years – Details Here ➤]( Today's market action… The Magnificent Six… Important data on tap… The opportunity in biotech… An investing breakthrough years in the making... Rank almost 5,000 stocks and beat the market… --------------------------------------------------------------- We'll get to the breakthrough in a moment... But first, let's look at today's market action... The tech-heavy Nasdaq Composite Index led, up about half a percentage point, the benchmark S&P 500 Index made a new all-time high, while the Dow Jones Industrial Average and small-cap Russell 2000 Index lagged and finished lower. A pleasant surprise from streaming service Netflix (NFLX) in its quarterly earnings report – 13.1 million new subscribers in the fourth quarter versus Wall Street expectations of less than 9 million – appears to be part of the catalyst for the action today... Netflix shares were up more than 12% intraday, but chipmaker Nvidia (up more than 2%), social media operator Meta Platforms (up roughly 1.5%), and tech giant Microsoft (up 1%) – each more heavily weighted in the Nasdaq than Netflix – also had something to do with it. For now, the story of early 2024 is looking familiar... Microsoft became a $3 trillion company at one point today... And Meta crossed the $1 trillion market-cap threshold for the first time since 2021. The "Magnificent Seven" (of which Netflix is not a part) are up across the board through the first few weeks of the year – except Tesla (TSLA), which was down 15% since New Year's Day through today's open. The company was set to report earnings at 5:30 p.m. today as our edition was going to press. This is just about the same tech-friendly story we saw during the bullish times of 2023. It might all be starting to feel like nothing can go wrong, which gets our attention as a warning. As I (Corey McLaughlin) [wrote on Monday]( stay sharp. Some volatility could be ahead. Market breadth is holding up, with roughly 60% of stocks listed on the New York Stock Exchange trading above their 200-day moving averages. But you can also find signals that the market isn't in a rip-roaring broad bull market. The equal-weight S&P 500 Index, for instance, is slightly down for the year and since mid-December. From the macro view... We mentioned earlier this week that we'd be watching for some key economic data to gauge where the broad market might go in the very short term. Tomorrow, the government will publish its GDP estimate for the fourth quarter of 2023. In recent quarters, these reports have tended to excite enough investors by continuing to show enough growth (and not recession). If we see the same tomorrow, I wouldn't be surprised if Mr. Market keeps on acting the way he has lately. If the GDP data is perceived differently, though, it could shake things up. And then the market might have a different reaction come Friday, when the Federal Reserve's preferred inflation gauge – the personal consumption expenditures ("PCE") index – is published... Should inflation numbers tick higher, more investors may decide that rate cuts might happen later than they previously thought. This could dent the major U.S. indexes in the short term. Alternatively, the inflation numbers may not upset the parlor game of predicting rate cuts. The Cleveland Fed's "Nowcast," for example, is expecting the PCE index to show a year-over-year inflation increase of 2.7% and a monthly increase of 0.27%. That's in line with the broader disinflationary trend since 2022 that has led folks to believe the Fed could be cutting rates soon. About that... Moving on to an opportunity in biotech... Stansberry Innovations Report editors John Engel and Eric Wade discussed interest rates [in their latest issue on Friday](... As they told subscribers, in the throes of the bear market that began in 2022 – coupled with the Fed's rapid rate hikes – capital funding for the speculative biotech sector all but dried up. But things are changing. As John and Eric said in the latest Innovations Report... We're seeing a decisive shift in the biotech space... And news from the 2024 JPMorgan Healthcare Conference indicates that the worst may be behind us. Several promising tailwinds are boosting the industry, including significant [mergers and acquisitions] and a change in the U.S. Federal Reserve's monetary policy. These factors – combined with a focus on cutting-edge tech advances – should rekindle major biotech deals and nurture research and development (R&D) in that space. As they alluded to, the Fed has something to do with this shift. In fact, they said it is the "likely most important" factor for the biotech industry (and many others, we would add)... Biotech companies rely heavily on debt for drug development. And the Fed's interest-rate hikes – which pushed short-term rates to multidecade highs – hit young, unprofitable companies the hardest. These conditions flushed out the biotech market... causing small, poorly capitalized companies to be acquired by larger, cash-rich enterprises looking to spur their own stagnating growth. And now... The central bank intends to cut interest rates in 2024 for the first time in four years, which could fuel positive momentum. There's an inverse relationship between interest rates and asset valuations. The higher the rate, the lower the present value of future cash flows, and the lower the valuations. Conversely, the lower the rate, the higher the value of future cash flows and the more likely investors are to reenter speculative investments. If you believe the Fed is going to cut rates in 2024 and are looking to put new money to work, the biotech sector is a logical place to invest – in the right stocks. While John and Eric aren't sure that the bottom is in for biotech quite yet, they said you don't need to time it perfectly... They detailed a great opportunity in their newest issue... We want to capitalize on these trends today by investing in an innovative and already-profitable software company that counts many of the top pharmaceutical companies as customers. Innovations Report subscribers and Stansberry Alliance members can find all the details on this recommendation [here](. Now, about the breakthrough years in the making... This is not hyperbole. Stansberry Research is celebrating its 25th year of business this year, and tomorrow, we'll be unveiling what at the very least is one of the biggest investment breakthroughs in company history. It started nearly a decade ago when our founder, Porter Stansberry, began systematically scanning thousands of companies using computers to find "capital efficient" stocks. Little did he realize that he would end up building a system that could deliver an easy-to-digest grade on nearly 5,000 stocks... And in recent years, our team has been working on taking this tool to a whole new level, with tests to get everything just right. The result has been something that has outperformed the market by up to 10-fold even through the sell-off of 2022. Stansberry Alliance members have been along for the ride most recently, and now we're ready to open access to this tool to all Stansberry Research subscribers. I can't give much away here (we'll plan to share more in the coming days), but all of the details will be shared tomorrow in a special event that has truly been years in the making. It is 100% free, and those who watch or listen will get two free recommendations, in addition to all the information about our tool. We just ask that you sign up in advance so you don't miss anything. [You can do so here](. In this week's episode of the Stansberry Investor Hour, Dan Ferris and I talk with Stansberry Research Director of Research Matt Weinschenk, who shares more insight on the big breakthrough that will be revealed tomorrow... [Click here to listen]( to this episode right now. For more free video content, [subscribe to our Stansberry Research YouTube channel](... and don't forget to follow us on [Facebook]( [Instagram]( [LinkedIn]( and [X, the platform formerly known as Twitter](. --------------------------------------------------------------- Recommended Links: [TOMORROW at 10 a.m. Eastern Time: Our Biggest Breakthrough in 25 Years]( It's a new way to see which of 4,817 stocks could double your money. Since going live, it has outperformed the market by up to 10-fold, gold by up to twice over, bitcoin by up to 20-fold, and has crushed almost all of the Magnificent Seven. [Join thousands of people to watch the unveiling tomorrow at 10 a.m. Eastern time](. --------------------------------------------------------------- [Gold Is Headed Above $3,000 per Ounce (Here's How to Play It)]( With so many strange events happening across the economy (the longest bear market for bonds since the Civil War... unprecedented bank closures... and soaring prices), it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – WITHOUT ever touching an ETF, mining stock, or even bullion. [Full details here](. --------------------------------------------------------------- New 52-week highs (as of 1/23/24): AbbVie (ABBV), Autodesk (ADSK), Amazon (AMZN), ASML (ASML), Berkshire Hathaway (BRK-B), Brown & Brown (BRO), CBOE Global Markets (CBOE), CyberArk Software (CYBR), Dorchester Minerals (DMLP), Alphabet (GOOGL), Microsoft (MSFT), Motorola Solutions (MSI), Oaktree Specialty Lending (OCSL), ProShares Ultra QQQ (QLD), Regeneron Pharmaceuticals (REGN), Roper Technologies (ROP), Invesco S&P 500 Equal Weight Technology Fund (RSPT), VanEck Semiconductor Fund (SMH), S&P Global (SPGI), Spotify Technology (SPOT), ProShares Ultra S&P 500 (SSO), Trane Technologies (TT), Tyler Technologies (TYL), ProShares Ultra Financials (UYG), Visa (V), Vanguard S&P 500 Fund (VOO), and Waste Management (WM). In today's mailbag, more feedback on [Argentine President Javier Milei's speech]( last week at the World Economic Forum... Do you have a comment or question? As always, e-mail us at feedback@stansberryresearch.com. "I read Corey's summary and couldn't agree more. But the fundamental problem is that mankind has fallen. I realize that idea is quite out-of-fashion, but it is true. The Davos crowd are all there for power. Money gives them power and they will do whatever is necessary to maintain or gain power..." – Subscriber Tim P. "Corey, Argentine President Javier Milei should have started his speech with a video clip of President Reagan's infamous press conference quip: 'The nine most terrifying words in the English language are: I'm from the Government, and I'm here to help.' "It certainly would have set the tone for his next 25 minutes of truthing that the Davos attendees weren't expecting. "Think he'll be invited back next year?" – Subscriber Christopher D. Corey McLaughlin comment: Thanks for the notes. Glad you asked the question, Christopher. No, I don't think Milei will be invited back next year, though I'd like to see it – to keep the conversation going, if nothing else. All the best, Corey McLaughlin Baltimore, Maryland January 24, 2024 --------------------------------------------------------------- Stansberry Research Top 10 Open Recommendations Top 10 highest-returning open positions across all Stansberry Research portfolios Stock Buy Date Return Publication Analyst MSFT Microsoft 11/11/10 1,330.5% Retirement Millionaire Doc MSFT Microsoft 02/10/12 1,263.4% Stansberry's Investment Advisory Porter wstETH Wrapped Staked Ethereum 02/21/20 1,011.3% Stansberry Innovations Report Wade ADP Automatic Data Processing 10/09/08 869.7% Extreme Value Ferris WRB W.R. Berkley 03/16/12 698.1% Stansberry's Investment Advisory Porter BRK.B Berkshire Hathaway 04/01/09 559.8% Retirement Millionaire Doc HSY Hershey 12/07/07 468.0% Stansberry's Investment Advisory Porter AFG American Financial 10/12/12 415.0% Stansberry's Investment Advisory Porter PANW Palo Alto Networks 04/16/20 363.1% Stansberry Innovations Report Engel BTC/USD Bitcoin 01/16/20 346.1% Stansberry Innovations Report Wade Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any Stansberry Research publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio. --------------------------------------------------------------- Top 10 Totals 4 Stansberry's Investment Advisory Porter 3 Stansberry Innovations Report Engel/Wade 2 Retirement Millionaire Doc 1 Extreme Value Ferris --------------------------------------------------------------- Top 5 Crypto Capital Open Recommendations Top 5 highest-returning open positions in the Crypto Capital model portfolio Stock Buy Date Return Publication Analyst wstETH Wrapped Staked Ethereum 12/07/18 2,053.7% Crypto Capital Wade ONE/USD Harmony 12/16/19 1,089.0% Crypto Capital Wade POLYX/USD Polymesh 05/19/20 1,038.1% Crypto Capital Wade BTC/USD Bitcoin 11/27/18 949.6% Crypto Capital Wade MATIC/USD Polygon 02/25/21 813.9% Crypto Capital Wade Please note: Securities appearing in the Top 5 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the Crypto Capital model portfolio. The buy date reflects when the recommendation was made, and the return shows its performance since that date. To learn if it's still a recommended buy today, you must be a subscriber and refer to the most recent portfolio. --------------------------------------------------------------- Stansberry Research Hall of Fame Top 10 all-time, highest-returning closed positions across all Stansberry portfolios Investment Symbol Duration Gain Publication Analyst Nvidia^* NVDA 5.96 years 1,466% Venture Tech. Lashmet Microsoft^ MSFT 12.74 years 1,185% Retirement Millionaire Doc Band Protocol crypto 0.32 years 1,169% Crypto Capital Wade Terra crypto 0.41 years 1,164% Crypto Capital Wade Inovio Pharma.^ INO 1.01 years 1,139% Venture Tech. Lashmet Seabridge Gold^ SA 4.20 years 995% Sjug Conf. Sjuggerud Frontier crypto 0.08 years 978% Crypto Capital Wade Binance Coin crypto 1.78 years 963% Crypto Capital Wade Nvidia^* NVDA 4.12 years 777% Venture Tech. Lashmet Intellia Therapeutics NTLA 1.95 years 775% Amer. Moonshots Root ^ These gains occurred with a partial position in the respective stocks. * The two partial positions in Nvidia were part of a single recommendation. Editor Dave Lashmet closed the first leg of the position in November 2016 for a gain of about 108%. Then, he closed the second leg in July 2020 for a 777% return. And finally, in May 2022, he booked a 1,466% return on the final leg. Subscribers who followed his advice on Nvidia could've recorded a total weighted average gain of more than 600%. You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.